טוען...
Experience with the Use of Nilotinib in Indian Patients
Important genetic and ethnic factors could affect the toxicity and efficacy of tyrosine kinase inhibitors. Though nilotinib has been available in India since 2010, there is no report on its safety and toxicity from Indian patients with chronic myeloid leukemia. This is an analysis of efficacy and to...
שמור ב:
| הוצא לאור ב: | Indian J Hematol Blood Transfus |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer India
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6081313/ https://ncbi.nlm.nih.gov/pubmed/30127550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-017-0877-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|